AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04415528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emotion-Focused Mindfulness Therapy
Description: EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention.
Study NCT04402008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Once Daily Dosing
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Study NCT04402008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Twice Daily Dosing
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Study NCT04402008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Study NCT01064193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~* Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~* Insert carefully the pipelle de Cornier® in the uterus through the cervix.~* Withdraw the piston to create a negative pression~* Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~* Withdraw the pipelle de Cornier® when filled with tissue~* Reinsert internal piston to deposit sample in cup filled with a fixative.
Study NCT01064193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
Study NCT02358369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost sustained release Ocular Insert
Study NCT02358369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Description: Bimatoprost sustained release Ocular Insert
Study NCT02358369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Description: BID drops OU, 0.5% ophthalmic solution
Study NCT02358369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Ocular Insert
Description: Placebo ocular insert OU.
Study NCT02358369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ocular Insert
Description: Placebo ocular insert OU.
Study NCT02358369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eye Drops
Description: Placebo eye drops BID OU.
Study NCT02152670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Study NCT02152670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Methyl Para Tyrosine (AMPT)
Study NCT02152670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]PHNO
Study NCT02152670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]raclopride
Study NCT04385914 — intervention group
Intervention type: OTHER
Intervention: COVID positive via testing
Description: Following pregnancy outcomes whether they are COVID positive or negative
Study NCT03716986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI Oxygen Saturation Map
Description: Calculation of the oxygen saturation map of gliomas cases
Study NCT02456545 — intervention group
Intervention type: OTHER
Intervention: ≥ 1 potential risk factor for BD
Description: exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
Study NCT02456545 — intervention group
Intervention type: OTHER
Intervention: depressive syndrome
Description: in- and outpatients with depressive syndrome
Study NCT02456545 — intervention group
Intervention type: OTHER
Intervention: ADHD
Description: in- and outpatients with ADHD
Study NCT00651404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
Study NCT00651404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
Study NCT03205826 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Type of sedation used
Description: All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
Study NCT03458832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FSHD-specific functional rating scale
Description: The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
Study NCT03458832 — intervention group
Intervention type: DEVICE
Intervention: Electrical Impedance Myography
Description: EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
Study NCT03501745 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WeChat
Description: Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
Study NCT02047630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic latanoprost
Study NCT02047630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic latanoprost
Study NCT02047630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brand-name latanoprost
Study NCT02047630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand-name latanoprost
Study NCT03616327 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MATRx in-lab, MATRx plus
Description: The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
Study NCT03982303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.
Study NCT02024191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Study NCT03816410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAA amputation
Description: complete surgical amputation of the left atrial appendage
Study NCT00235690 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draws
Description: PK samples obtained around a clinical dosing of colistin
Study NCT00235690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: PK blood samples will be obtained around a clinical dosing of colistin
Study NCT03583372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: single daily dose 75 mg
Study NCT03583372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebos
Description: placebo to match vibegron (experimental drug) and tolterodine (active comparator)
Study NCT03583372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebos
Description: placebo to match vibegron (experimental drug) and tolterodine (active comparator)
Study NCT03583372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate ER
Description: single daily dose of 4 mg
Study NCT02685891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Playing tones during deep sleep
Description: Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
Study NCT02685891 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham condition
Description: in the sham condition, no tones will be played
Study NCT03296787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.
Study NCT03408951 — intervention group
Intervention type: OTHER
Intervention: Recording
Description: The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
Study NCT03712501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 60 minute walk at 60% maximal oxygen uptake.
Study NCT01248910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alpine Skiing
Study NCT04143620 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure
Description: Triple procedure
Study NCT00831441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Tablets, Oral, 5 mg, twice daily, until study end
Study NCT00831441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, until study end
Study NCT03119844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
Study NCT03119844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Phototherapy
Description: Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
Study NCT03119844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Phototherapy
Description: Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
Study NCT00236119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 20mg
Description: Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
Study NCT00236119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 40mg
Description: Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
Study NCT00236119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 60mg
Description: Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
Study NCT00236119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 80mg
Description: Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
Study NCT03338114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX-787-ODT (orally disintigrating tablet)
Description: Oral Disintegrating Tablet
Study NCT03665779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate
Description: 70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
Study NCT03665779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
Study NCT03119558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben (Neuraceq®) PET/MRI
Description: Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
Study NCT01366898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasona, Idarubicine, ARA-C, Methotrexate
Study NCT01559987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manual Toothbrush only
Description: ADA (American Dental Association) Reference Manual Toothbrush (MTB)
Study NCT01559987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTB + Waterpik Ultra Water Flosser 'High'
Description: MTB + Waterpik Ultra Water Flosser 'High'
Study NCT01559987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MTB + Floss (MTB+Floss)
Description: MTB + Floss (MTB+Floss)
Study NCT01046552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative ERCP and LC
Description: preoperative ERCP followed by LC
Study NCT01046552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative ERCP and LC
Description: LC and intraoperative ERCP
Study NCT01520636 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard physiotherapy
Description: daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
Study NCT01520636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental physiotherapy
Description: physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
Study NCT05443100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation (WBC)
Description: Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
Study NCT05443100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Multidisciplinary rehabilitation program consisting of diet and physical exercise.
Study NCT03697330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood.
Study NCT00979381 — intervention group
Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: influenza vaccination
Study NCT00845975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia Hearing Lasers #1 & #2
Description: Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site.
Study NCT00845975 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lasers
Description: The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
Study NCT04088123 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor Oral Tablet [Brilinta]
Description: A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
Study NCT04643340 — intervention group
Intervention type: OTHER
Intervention: real-time fMRI
Description: Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
Study NCT04320771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
Study NCT03687892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation
Description: Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
Study NCT03687892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
Study NCT01168154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuterii
Description: Lactobacillus Reuterii 10000000000 CFU per day
Study NCT01168154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02804425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: actor-spectator
Description: actor-spectator group : actor at least once during the simulation session
Study NCT02748590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim II Neurostimulator Model 3058
Description: The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
Study NCT02847897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 AcuPulse Laser
Description: Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
Study NCT04396730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oil
Description: 400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
Study NCT04396730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol Oil
Description: 400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
Study NCT04396730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered daily along with oral contraceptives daily for 24 days.
Study NCT04396730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered daily along with oral contraceptives daily for 24 days.
Study NCT04396730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Description: All participants will receive oral contraceptives
Study NCT04396730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined oral contraceptive pill
Description: All participants will receive oral contraceptives